Cargando…
The antiviral effects of RSV fusion inhibitor, MDT‐637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin
BACKGROUND: Respiratory syncytial virus (RSV) viral load and disease severity associate, and the timing of viral load and disease run in parallel. An antiviral must be broadly effective against the natural spectrum of RSV genotypes and must attain concentrations capable of inhibiting viral replicati...
Autores principales: | Kim, Young‐In, Pareek, Rajat, Murphy, Ryan, Harrison, Lisa, Farrell, Eric, Cook, Robert, DeVincenzo, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705693/ https://www.ncbi.nlm.nih.gov/pubmed/28990339 http://dx.doi.org/10.1111/irv.12503 |
Ejemplares similares
-
Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis
por: Pickles, Raymond J, et al.
Publicado: (2015) -
RSV infection without ribavirin treatment in pediatric hematopoietic stem cell transplantation
por: El-Bietar, J, et al.
Publicado: (2016) -
1600. An Optimal Respiratory Syncytial Virus (RSV) Treatment in Lung Transplant Recipients: Oral Ribavirin, Inhaled Ribavirin, or Conservative Approach
por: Permpalung, Nitipong, et al.
Publicado: (2018) -
923. EDP-938, A Respiratory Syncytial Virus (RSV) antiviral, demonstrates a high barrier to resistance in a human challenge study
por: Levene, Rachel E, et al.
Publicado: (2023) -
Use of Oral Ribavirin for the Treatment of RSV Infections in Hematopoietic Cell Transplant (HCT) Recipients
por: Foolad, Farnaz, et al.
Publicado: (2017)